EJC Supplements
Volume 9, Issue 2 , Pages 22-29, October 2011

New treatment strategies in the management of breast cancer

  • Edith A. Perez

      Affiliations

    • Corresponding Author InformationCorrespondence: Edith A. Perez, Deputy Director, Mayo Clinic Cancer Center, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. Tel.: +1 904 953 7283; fax: +1 904 953 6233

Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, Florida, USA

Article Outline

Abstract 

Growing understanding of the molecular characteristics of breast cancer is raising the possibility of ultimately delivering therapies that are tailored to the tumour biology of the individual patient. Agents that are currently being evaluated in metastatic breast cancer, irrespective of specific markers such as human epidermal growth factor receptor-2 (HER2) or oestrogen receptor, include the novel microtubule inhibitor eribulin mesylate, and a monoclonal antibody directed against vascular endothelial growth factor-A, bevacizumab. Denosumab, a receptor activator of nuclear factor (B ligand (RANKL) inhibitor, has recently been demonstrated to improve bone-related métastases in patients with breast cancer, irrespective of biological phenotype. Targeted therapies directed against DNA repair mechanisms such as poly(ADP ribose) polymerase (PARP) may prove particularly useful in the treatment of triple-negative breast cancer. Turning to the adjuvant setting in patients with HER2-positive breast cancer, recent studies have shown that concomitant treatment with taxanes and trastuzumab improves survival, and data with novel anti-HER2 agents are emerging. Current adjuvant and metastatic studies are evaluating novel targeted treatments aimed at HER2 and other targets. Molecular profiling of tumours is providing and will further provide the needed answers related to therapeutic optimisation.

Keywords:  Adjuvant , Breast cancer , Breast neoplasms , Chemotherapy , DNA repair , Eribulin , HER2 , Lapatinib , Neoadjuvant , Poly(ADP ribose) polymerases , Trastuzumab

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Talmadge JE , Fidler IJ . AACR centennial series: the biology of cancer metastasis: historical perspective . Cancer Res . 2010;70:5649–5669
  2. Novartis drug Afmitor® met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need [press release]. Basel, Switzerland: Novartis Oncology; 05 July 2011 . Available at: http://www.novartis.com/newsroom/media-releases/en/2011/1528340.shtml Accessed 16 August 2011.
  3. Kurzrock R, Wheler J, Gabrail N, et al. ANG1005, a conjugate of Angiopep-2 and paclitaxel: development of a new chemical entity for the treatment of advanced solid tumors and brain métastases. Proc Am Assoc Cancer Res 2009; 100th AACR Annual Meeting Apr 18-22; Denver, Colorado:abs 3782.
  4. Jimeno A . Eribulin: rediscovering tubulin as an anticancer target . Clin Cancer Res . 2009;15:3903–3905
  5. Cortes J , O'Shaughnessy J , Loesch D , et al.   Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study . Lancet . 2011;377:914–923
  6. Yang SX . Bevacizumab and breast cancer: current therapeutic progress and future perspectives . Expert Rev Anticancer Ther . 2009;9:1715–1725
  7. O'Shaughnessy J , Miles D , Gray RJ , et al.   A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) . J Clin Oncol . 2010;28(15 Suppl):1005
  8. Brufsky AM . The evolving role of bone-conserving therapy in patients with breast cancer . Semin Oncol . 2010;37(Suppl 1):S12–S19
  9. Stopeck AT , Lipton A , Body J-J , et al.   Denosumab compared with zoledronic acid for the treatment of bone métastases in patients with advanced breast cancer: a randomized, double-blind study . J Clin Oncol . 2010;28:5132–5139
  10. Sørlie T , Tibshirani R , Parker J , et al.   Repeated observation of breast tumor subtypes in independent gene expression data sets . Proc Natl Acad Sci USA . 2003;100:8418–8423
  11. Nielsen TO , Hsu FD , Jensen K , et al.   Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma . Clin Cancer Res . 2004;10:5367–5374
  12. Dent R , Trudeau M , Pritchard KI , et al.   Triple-negative breast cancer: clinical features and patterns of recurrence . Clin Cancer Res . 2007;13:4429–4434
  13. Hines SL , Vallow LA , Tan WW , McNeil RB , Perez EA , Jain A . Clinical outcomes after a diagnosis of brain métastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer . Ann Oncol . 2008;19:1561–1565
  14. Helleday T , Petermann E , Lundin C , Hodgson B , Sharma RA . DNA repair pathways as targets for cancer therapy . Nat Rev Cancer . 2008;8:193–204
  15. Bryant HE , Schultz N , Thomas HD , et al.   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase . Nature . 2005;434:913–917
  16. Farmer H , McCabe N , Lord CJ , et al.   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy . Nature . 2005;434:917–921
  17. O'Shaughnessy J , Osborne CK , Pippen JE , et al.   Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triplenegative breast cancer (TNBC): results of a randomized phase II trial . J Clin Oncol . 2009;27(18 Suppl): abs 3.
  18. O'Shaughnessy J , Osborne C , Pippen JE , et al.   Iniparib plus chemotherapy in metastatic triple-negative breast cancer . N Engl J Med . 2011;364:205–214
  19. National Institutes of Health, ClinicalTrials.gov website. Clinical Trial Registration: NCT01091454. Available at: http://clinicaltrials.gov Accessed 18 July 2011.
  20. National Institutes of Health, ClinicalTrials.gov website. Clinical Trial Registration: NCT011105312i. Available at: http://clinicaltrials.gov Accessed 18 July 2011.
  21. Santana-Davila R , Perez EA . Treatment options for patients with triple-negative breast cancer . J Hematol Oncol . 2010;3:42
  22. Yin L , Velazquez OC , Liu ZJ . Notch signaling: emerging molecular targets for cancer therapy . Biochem Pharmacol . 2010;80:690–701
  23. Fong PC , Boss DS , Yap TA , et al.   Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers . N Engl J Med . 2009;361:123–134
  24. Fang L , Barekati Z , Zhang B , et al.   Targeted therapy in breast cancer: what's new? . Swiss Med Wkly . 2011;141:W13231
  25. Perez EA , Roche PC , Jenkins CA , et al.   HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization . Mayo Clin Proc . 2002;77:148–154
  26. Lai P , Tan LK , Chen B . Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas . Am J Clin Pathol . 2005;123:541–546
  27. Arpino G , Green SJ , Allred DC , et al.   HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study . Clin Cancer Res . 2004;10:5670–5676
  28. Perez EA , Suman VJ , Davidson NE , et al.   Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer . J Clin Oncol . 2011; In press.
  29. Wolff AC , Hammond EH , Schwartz JN , et al.   American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer . J Clin Oncol . 2007;25:118–145
  30. Bevers TB , Anderson BO , Bonaccio E , et al.   NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis . J Natl Compr Cancer Netw . 2009;7:1060–1096
  31. Trastuzumab Prescribing Information . Available at: http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf 2009; Accessed 4 October 2010.
  32. Perez EA , Reinholz MM , Hillman DW , et al.   HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial . J Clin Oncol . 2010;28:4307–4315
  33. Perez EA , Dueck AC , Press MF , et al.   Round-robin review of HER2 testing in the context of adjuvant therapy for breast cancer (NCCTG N9831/BCIRG006/BCIRG005) . Cancer Res . 2010;70(24 Suppl): abs PD10-02.
  34. Perez EA , Dueck AC , Reinholz MM , et al.   Impact of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831 . J Clin Oncol . 2011;29(15 Suppl): abs 10504.
  35. Reinholz MM , Dueck AC , Chen B , et al.   Impact of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial . J Clin Oncol . 2011;29(15 Suppl): abs 10503.
  36. Piccart-Gebhart MJ , Procter M , Leyland-Jones B , et al.   Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer . N Engl J Med . 2005;353:1659–1672
  37. Smith I , Procter M , Gelber RD , et al.   2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial . Lancet . 2007;369:29–36
  38. Gianni L , Goldhirsch A , Gelber RD , et al.   Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer . Breast . 2009;18(Suppl 1):S11; (abs S25).
  39. Slamon D , Eiermann W , Robert N , et al.   Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC?T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC?TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study . Cancer Res . 2009;69(24 Suppl 3): abs 62.
  40. Russell SD , Blackwell KL , Lawrence J , et al.   Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials . J Clin Oncol . 2010;28:3416–3421
  41. Morris PG , Hudis CA . Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? . J Clin Oncol . 2010;28:3407–3410
  42. Tomasello G , de Azambuja E , Dinh P , Snoj N , Piccart-Gebhart M . Jumping higher: is it still possible? The ALTTO trial challenge . Expert Rev Anticancer Ther . 2008;8:1883–1890
  43. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 8-12 December 2010:abs S3-3.
  44. Goss PE , Barrios CH , Chan A , et al.   A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC) . J Clin Oncol . 2011;29(15 Suppl): absTPS137.
  45. Gianni L , Lladó A , Bianchi G , et al.   Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer . J Clin Oncol . 2010;28:1131–1137
  46. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 8-12 December 2010:abs S3-2.
  47. Junttila TT , Li G , Parsons K , Phillips GL , Sliwkowski MX . Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer . Breast Cancer Res Treat . 2011;128:347–356
  48. Perez EA , Dirix L , Kocsis J , et al.   Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450G) . Ann Oncol . 2010;21(Suppl 8): abs LBA3.
  49. Andorfer CA , Necela BM , Thompson EA , et al.   MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer . Trends Mol Med . 2011;17:313–319
  50. Sun Z , Asmann YW , Kalari KR , et al.   Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing . PLoS ONE . 2011;6(2): e17490.
  51. Asmann YW, Hossain A, Necela BM, et al. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res 2011 May 27 [Epub ahead of print].

PII: S1359-6349(11)70006-4

doi:10.1016/S1359-6349(11)70006-4

EJC Supplements
Volume 9, Issue 2 , Pages 22-29, October 2011

Article Tools